



Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting

November 3, 2022

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design *de novo* protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.

Oral presentation details are as follows:

Title: NEO-TRA1: A CD25-Targeted *De Novo* non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells
Session Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans
Publication Number: 684
Session Date/Time: Monday, December 12, 2022, 11:45 AM
Location: Ernest N. Morial Convention Center, 278-282

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using *de novo* protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media

Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors

Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com



Source: Neoleukin Therapeutics, Inc.